Table 1.
Comparisons of clinical characteristics between non-AKI and AKI patients with RM induced by EHS.
| Non-AKI (n = 43) | AKI (n = 41) | p-Value | |
|---|---|---|---|
| APACHE II score, median (IQR) | 9.0 (7.0–14.0) | 17.0 (11.0–22.0) | <0.001 |
| SOFA score, median (IQR) | 3.0 (2.0–4.0) | 9.0 (5.0–11.0) | <0.001 |
| GCS score, median (IQR) | 12.0 (9.0–14.0) | 8.0 (6.0–12.0) | 0.006 |
| Age (years), median (IQR) | 21.0 (19.0–26.5) | 23.0 (20.0–28.0) | 0.056 |
| WBC (1 × 109/L), median (IQR) | 11.6 (8.9–14.3) | 12.0 (9.2–14.9) | 0.209 |
| Neutrophil (1 × 109/L), median (IQR) | 8.8 (7.0–12.5) | 10.0 (6.9–13.3) | 0.187 |
| Lymphocyte (1 × 109/L), median (IQR) | 1.1 (0.7–1.7) | 0.7 (0.4–1.7) | 0.759 |
| Monocytes (1 × 109/L), median (IQR) | 0.7 (0.5–1.0) | 0.7 (0.4–1.0) | 0.549 |
| Platelets (1 × 109/L), median (IQR) | 152.0 (89.0–199.0) | 80.0 (38.0–115.5) | <0.001 |
| Mean platelet volume, median (IQR) | 10.7 (10.0–11.5) | 10.8 (10.1–11.3) | 0.987 |
| Platelet distribution width, median (IQR) | 12.6 (11.1–13.6) | 12.5 (11.1–14.3) | 0.514 |
| TBIL (µmol/L), median (IQR) | 16.6 (12.4–25.8) | 24.4 (14.2–62.9) | 0.079 |
| ALT (U/L), median (IQR) | 54.0 (24.5–333.0) | 148.0 (57.0–1771.0) | 0.014 |
| AST (U/L), median (IQR) | 118.0 (64.0–483.0) | 290.0 (115.0–1587.0) | 0.014 |
| BUN (mmol/L), median (IQR) | 5.1 (4.2–6.1) | 7.8 (6.4–10.3) | <0.001 |
| Scr (µmol/L), median (IQR) | 93.0 (78.0–107.5) | 187.0 (151.0–263.0) | <0.001 |
| Cystatin C (mg/L), median (IQR) | 0.9 (0.8–1.0) | 1.2 (1.0–1.8) | <0.001 |
| CK (U/L), median (IQR) | 2434.0 (1462.5–4714.5) | 3506.0 (1614.0–7894.0) | 0.780 |
| CK-MB (ng/ml), median (IQR) | 63.0 (41.5–107.0) | 89.0 (56.5–209.5) | 0.040 |
| MB (ng/ml), median (IQR) | 466.0 (174.0–1000.0) | 1000.0 (979.8–1000.0) | <0.001 |
| cTNI (pg/ml), median (IQR) | 60.0 (11.0–210.0) | 580.0 (195. 0–1103.5) | 0.018 |
| PT (s), median (IQR) | 16.3 (15.3–18.9) | 23.0 (17.1–36.9) | 0.017 |
| INR (median (IQR) | 1.5 (0.6) 1.3 (1.2–1.6) | 2.0 (1.4–3.7) | <0.001 |
| APTT (s), median (IQR) | 41.0 (36.5–46.8) | 49.9 (38.3–85.4) | 0.299 |
| TT(s), median (IQR) | 17.5 (16.6–23.4) | 21.8 (17.1–36.5) | 0.045 |
| FIB (g/L), median (IQR) | 2.6 (2.3–3.0) | 2.1 (1.4–2.6) | 0.002 |
| D-dimer (mg/L), median (IQR) | 1.1 (0.6–3.9) | 10.0 (3.7–14.4) | <0.001 |
| CRP (mg/dl), median (IQR) | 4.2 (3.2–7.7) | 3.4 (2.4–6.4) | 0.366 |
| PCT (ng/ml), median (IQR) | 2.5 (1.1–4.3) | 3.7 (1.6–6.8) | 0.734 |
| MB ≥ 1000 ng/ml, N (%) | 10/37 (27.0%) | 26/35 (74.3%) | <0.001 |
| Lymphocytopenia, N (%) | 16/43 (37.2%) | 21/40 (52.5%) | 0.161 |
| DIC, N (%) | 10/32(31.2%) | 24/32(75.0%) | <0.001 |
| AHI, N (%) | 31/41 (75.6%) | 29/39 (74.4%) | 0.897 |
| 90-day mortality, N (%) | 0/43 (0.0%) | 14/41 (34.1%) | <0.001 |
| ICU time (d), median (IQR) | 5.0 (3.0–7.5) | 7.5 (5.0–13.5) | 0.023 |
| Survival time (d), median (IQR) | 90.0 (90.0–90.0) | 90.0 (9.0–90.0) | <0.001 |
| Hospitalization costs (RMB), median (IQR) | 36 748.7 (22 408.4–64 406.8) | 113 013.1 (45 869.3–224 580.8) | <0.001 |
APACHE II: Acute Physiology and Chronic Health Evaluation II; SOFA: Sequential Organ Failure Assessment; GCS: Glasgow Coma Scale; WBC: white blood cell; TBIL: total bilirubin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; BUN: blood urea nitrogen; Scr: serum creatinine; CK: creatine kinase; CK-MB: MB isoenzyme of creatine kinase; MB: myoglobin; cTNI: cardiac troponin I; PT: prothrombin time; INR: international normalized ratio; APTT: activated partial thromboplastin time; TT: thrombin time; FIB: fibrinogen; CRP: C-reactive protein; PCT: procalcitonin. DIC: disseminated intravascular coagulation; AHI: acute hepatic injury.